April 27, 2021 11:43 AM EDTUpdated 11:56 AM
Pharma

Eli Lil­ly shares take a hit as com­pa­ny low­ers full-year fore­cast

Nicole DeFeudis

Editor

The roll­out of Covid-19 vac­cines and the de­ci­sion to halt dis­tri­b­u­tion of its an­ti­body ther­a­py has left Eli Lil­ly with some dis­ap­point­ing news to share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times